FocalTherics (NASDAQ:FOCL) Stock Rating Upgraded by Wall Street Zen
by Renee Jackson · The Cerbat GemFocalTherics (NASDAQ:FOCL – Get Free Report) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a report issued on Saturday.
Other analysts have also issued reports about the company. Mizuho set a $15.00 price objective on FocalTherics and gave the company an “outperform” rating in a report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of FocalTherics in a report on Tuesday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, FocalTherics currently has an average rating of “Moderate Buy” and a consensus target price of $9.00.
Read Our Latest Stock Report on FOCL
FocalTherics Stock Performance
Shares of NASDAQ:FOCL opened at $6.12 on Friday. FocalTherics has a 1 year low of $1.21 and a 1 year high of $6.36. The business’s 50-day moving average price is $5.24. The company has a quick ratio of 0.99, a current ratio of 1.34 and a debt-to-equity ratio of 1.79. The stock has a market cap of $229.38 million, a PE ratio of -7.56 and a beta of -0.04.
FocalTherics (NASDAQ:FOCL – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The business had revenue of $20.48 million for the quarter, compared to analyst estimates of $19.46 million. FocalTherics had a negative net margin of 41.47% and a negative return on equity of 137.61%. Analysts predict that FocalTherics will post -0.78 earnings per share for the current year.
Insider Buying and Selling at FocalTherics
In other news, Director Joshua Levine bought 10,000 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were purchased at an average cost of $4.22 per share, with a total value of $42,200.00. Following the completion of the acquisition, the director directly owned 35,000 shares in the company, valued at approximately $147,700. The trade was a 40.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 10.10% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On FocalTherics
Hedge funds and other institutional investors have recently modified their holdings of the stock. Leonteq Securities AG acquired a new position in FocalTherics in the 4th quarter worth approximately $313,000. Kovack Advisors Inc. purchased a new stake in FocalTherics in the 4th quarter worth approximately $53,000. Rock Springs Capital Management LP raised its stake in shares of FocalTherics by 1.3% during the 4th quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the company’s stock worth $4,233,000 after purchasing an additional 16,500 shares in the last quarter. Flax Pond Capital LLC bought a new position in shares of FocalTherics during the 4th quarter valued at $2,623,000. Finally, SmartHarvest Portfolios LLC bought a new position in shares of FocalTherics during the 1st quarter valued at $38,000. Institutional investors and hedge funds own 62.74% of the company’s stock.
FocalTherics Company Profile
EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.